<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<body bgcolor="#FFFFFF">
<page>
<p align="center"><font size="2" face="serif">SECURITIES AND EXCHANGE COMMISSION<br>WASHINGTON, D.C. 20549</font></p>
<p align="center"><font size="2" face="serif">____________________</font></p>
<p align="center"><font size="2" face="serif">FORM 8-K</font></p>
<p align="center"><font size="2" face="serif">CURRENT REPORT<br>PURSUANT TO SECTION 13 OR 15(d) OF<br>THE SECURITIES EXCHANGE ACT OF 1934</font></p>
<p align="center"><font size="2" face="serif">Date of Report (Date of earliest event reported):  November 7, 2005</font></p>
<table width="100%" border="0" align="center" cellpadding="0" cellspacing="0">
<tr valign="top">
  <td align="center"><font size="2" face="serif">Savient Pharmaceuticals, Inc.</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr size="1" noshade></td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Exact name of registrant as specified
    in charter)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
  <td align="center">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="center">&nbsp;</td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">Delaware</font></td>
<td width="30%" align="center"><font size="2" face="serif">0-15313                </font></td>
<td width="30%" align="center"><font size="2" face="serif">13-3033811</font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
  <td align="center"><hr size="1" noshade></td>
  <td align="center"><hr size="1" noshade></td>
  <td align="center"><hr size="1" noshade></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="center"><font size="2" face="serif">(State or other juris-<br>diction of incorporation</font></td>
<td align="center"><font size="2" face="serif">(Commission<br>File Number)</font></td>
<td align="center"><font size="2" face="serif">(IRS Employer<br>Identification No.)</font></td>
</tr>
</table>


<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td align="center" valign="bottom">&nbsp;</td>
  </tr>
  <tr>
    <td align="center" valign="bottom"><font size="2">One Tower Center, 14th Floor<br>
      East Brunswick, New Jersey 08816</font></td>
  </tr>
  <tr>
    <td align="center" valign="bottom"><hr size="1" noshade></td>
  </tr>
  <tr>
    <td align="center" valign="bottom"><font size="2">(Address of principal executive offices)
      (Zip Code)</font></td>
  </tr>
</table>
<p align="center"><font size="2" face="serif">Registrant&#8217;s telephone number, including area code:  (732) 418-9300</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="2" face="serif">Not applicable</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr size="1" noshade></td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Former name or former address, if changed since last report)</font></td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p?"></a>
<p>&nbsp;</p>
<p align="left"><font size="2" face="serif"><b>Item 2.02.  Results of Operations and Financial Condition</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November 7, 2005, Savient Pharmaceuticals, Inc. (&#8220;Savient&#8221;) announced a business update, in which it provided a financial overview for the quarter ended September 30, 2005 and discussed recent strategic developments. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, on&nbsp;November 7, 2005, Savient held a publicly available live webcast discussion of&nbsp;this business overview. The transcript of the&nbsp;November 7, 2005 conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information in this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</font></p>
<p align="left"><font size="2" face="serif"><b>Item 9.01.  Financial Statements And Exhibits</b></font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="5%">&nbsp;</td>
    <td width="12%"><font size="2" face="serif">&nbsp;(c) &nbsp;Exhibits</font></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center"><font size="2" face="serif">&nbsp;99.1</font></td>
    <td><font size="2" face="serif">Press
release dated November 7, 2005</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center"><font size="2" face="serif">99.2</font></td>
    <td><font size="2" face="serif">Transcript dated November 7, 2005</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
</table>
<p align="left">&nbsp;</p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;    </font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p?"></a>
<p>&nbsp;</p>
<p align="center"><font size="2" face="serif">SIGNATURE</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="50%"><font size="2" face="serif">Date: November 8, 2005</font></td>
    <td colspan="2"><font size="2" face="serif">SAVIENT PHARMACEUTICALS, INC.</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td width="5%">&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><font size="2" face="serif">By</font>:</td>
    <td><font size="2" face="serif">/s/ Philip K. Yachmetz</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><hr size="1" noshade></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font size="2" face="serif">Philip K. Yachmetz</font><br>
      <font size="2" face="serif">Senior Vice President, General Counsel and
    Secretary</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
</table>
<p align="left"><font size="2" face="serif"></font></p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p?"></a>
<p>&nbsp;</p>
<p align="center"><font size="2" face="serif">EXHIBIT INDEX</font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top" bgcolor="#FFFFFF">
<td width="8%" align="left"><font size="2" face="serif"><u>Exhibit No.</u></font></td>
<td width="58%" align="left"><font size="2" face="serif"><u>Description</u></font></td>
<td width="2%" align="left">&nbsp;</td> </tr>
<tr valign="top">
<td></td>
<td>&nbsp;</td>
<td></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">99.1</font></td>
<td align="left"><font size="2" face="serif">Press release dated November 7, 2005</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">99.2</font></td>
<td align="left"><font size="2" face="serif">Transcript dated November 7, 2005</font></td>
<td align="left">&nbsp;</td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b409653_8k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 8656}]
{"company-data": {"conformed-name": "SAVIENT PHARMACEUTICALS INC", "cik": "0000722104", "assigned-sic": "2833", "irs-number": "133033811", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-15313", "film-number": "051186825"}, "business-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816", "phone": "7324189300"}, "mail-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816"}, "former-company": {"former-conformed-name": "BIO TECHNOLOGY GENERAL CORP", "date-changed": "19920703"}}
Prepared and filed by St Ives Financial
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):  November 7, 2005
Savient Pharmaceuticals, Inc.
(Exact name of registrant as specified
    in charter)
Delaware
0-15313
13-3033811
(State or other juris-
diction of incorporation
(Commission
File Number)
(IRS Employer
Identification No.)
One Tower Center, 14th Floor
East Brunswick, New Jersey 08816
(Address of principal executive offices)
      (Zip Code)
Registrant's telephone number, including area code:  (732) 418-9300
Not applicable
(Former name or former address, if changed since last report)
Item 2.02.  Results of Operations and Financial Condition
On November 7, 2005, Savient Pharmaceuticals, Inc. ("Savient") announced a business update, in which it provided a financial overview for the quarter ended September 30, 2005 and discussed recent strategic developments. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In addition, on November 7, 2005, Savient held a publicly available live webcast discussion of this business overview. The transcript of the November 7, 2005 conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.  Financial Statements And Exhibits
(c)  Exhibits
99.1
Press
release dated November 7, 2005
99.2
Transcript dated November 7, 2005
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 8, 2005
SAVIENT PHARMACEUTICALS, INC.
By
:
/s/ Philip K. Yachmetz
Philip K. Yachmetz
Senior Vice President, General Counsel and
    Secretary
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press release dated November 7, 2005
99.2
Transcript dated November 7, 2005